Inventiva vs Rani Therapeutics Holdings
Inventiva is the larger business, with $5.1m of revenue in fiscal 2025 against $1.6m for Rani Therapeutics Holdings (3.1 times as much). Rani Therapeutics Holdings grew faster (58.9% against -49.1%). Rani Therapeutics Holdings kept more of each dollar of sales as profit: a net margin of -1817.1% against -7899.6%.
| Latest fiscal year | InventivaIVA, 2025 | Rani Therapeutics HoldingsRANI, 2025 |
|---|---|---|
| Revenue | $5.1m | $1.6m |
| Revenue growth | -49.1% | 58.9% |
| Net income | −$400m | −$29.7m |
| Operating margin | -3145.5% | -2346.0% |
| Net margin | -7899.6% | -1817.1% |
| Return on equity | — | -169.6% |
| Free cash flow | — | −$18.8m |
| Cash | $117m | $18.6m |
| Total debt | $70.3m | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 69 |
| Market value | $795m | $104m |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 0 buys, 0 sales | 2 buys, 1 sales |